Medical Advocates for Social Justice
Conference Abstract
from the
2nd IAS Conference on HIV and Pathogenesis
Paris, France

July 14-17, 2003
 

 

Standard Does of Efavirenz (EFV), Zidovudine (ZDV), Tenofovir
(TDF), and  Didanosine (ddI) May Be Given with Tipranavir/
Ritonavir (TPV/r).


PJ Roszko1, K Curry1, B Brazina2, A Cohen3, E l-Turkie4, JP Sabo1,
 TR MacGregor1, S McCallister
1
1Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT;
2
Northwest Kinetics, Tacoma, WA;
3
Peninsular Testing Corp., Miami, FL;
4
Acumen Pharmaceutical Services Ltd., Manchester, UK.

 

Share this Abstract with a Colleague
 

Introduction:
Tipranavir (TPV) is the first non-peptidic protease inhibitor (NPPI); it has demonstrated a uniquely robust resistance profile in single and multiple protease inhibitor–experienced patients. TPV is administered with low-dose ritonavir (RTV) to optimize plasma concentrations. TPV is an inducer of, and RTV is a potent inhibitor of CYP3A4. Coadministration results in net inhibition of CYP3A4. The interactions between TPV/r and EFV, ZDV, TDF, or ddI (EC) at manufacturer recommended doses, are reported here.

Methods:
HIV-negative, healthy volunteers were recruited to 1 of 4 open-label, randomized, parallel-group trials. Subjects in each trial were randomized to receive either TPV/r 500 mg/100 mg or TPV/r 750 mg/200 mg. Studies of ZDV, TDF, and ddI had pharmacokinetic (PK) sampling on day 1 for the NRTI alone, on day 12 or 14 for TPV/r alone (steady state), and on day 13 or 15 for the drugs in combination. In the EFV trial, PK sampling occurred after both single dose (days 1, 3, and 5) and at steady state (days 14 and 21).

Results:
The EFV, ZDV, TDF, and ddI trials enrolled 68, 60, 49, and 23 healthy volunteers, respectively. The PK profile of TPV/r was unchanged by EFV following a single dose; EFV was also unchanged. Increases in TPV AUC, Cmax, and C12h were seen at steady state with EFV. TPV/r caused a 56%–61% reduction in ZDV Cmax and a 33%–43% reduction in AUC. ZDV did not affect the PK of TPV/r. A dose-dependent reduction in TDF Cmax of 23%–38% was shown, while there was a 17% decrease in TPV at the 500/100 dose and an 11% decrease with the 750/200 dose. No change in the PK profile of ddI was seen with TPV/r; although no change in TPV/r AUC was seen in this study, there was a 32% increase in TPV Cmax and a 34% decrease in TPV C12h

Conclusions:
When the enteric-coated formulation of ddI is used, administration should be 4 hours apart from TPV/r.  Standard doses of EFV, ZDV, TDF and ddI may be used with TPV/r.


Main New/Newsworthy Tipranavir Main Page IAS Conference Index      


Standard Does of Efavirenz (EFV), Zidovudine (ZDV), Tenofovir (TDF),
and  Didanosine (ddI) May Be Given with Tipranavir/Ritonavir (TPV/r).

A Medical Advocates for Social Justice Update